ArriVent BioPharma Inc. logo

ArriVent BioPharma Inc.

AVBP | NASDAQ
Chart Builder DCF Calculator
$29.74
+$0.84 (+2.91%)
At close: Sep 21, 2026, 4:00 PM ET
$29.70
-$0.04 (-0.13%)
Pre-market: Sep 22, 2026, 8:21 AM ET
Fiscal Quarter
Period Ending
Q2 2026
Jun 29, 2026
Q1 2026
Mar 30, 2026
Q4 2025
Dec 30, 2025
Q3 2025
Sep 29, 2025
Q2 2025
Jun 29, 2025
Q1 2025
Mar 30, 2025
Q4 2024
Dec 30, 2024
Q3 2024
Sep 29, 2024
Q2 2024
Jun 29, 2024
Q1 2024
Mar 30, 2024
Q4 2023
Dec 30, 2023
Q3 2023
Sep 29, 2023
Q2 2023
Jun 29, 2023
Q1 2023
Mar 30, 2023
Q4 2022
Dec 30, 2022
Q3 2022
Sep 29, 2022
Q2 2022
Jun 29, 2022
Q1 2022
Mar 30, 2022
Revenue
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Gross Profit
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Income
-52.69M -46.11M -38.82M -38.32M -33.62M -66.77M -23.71M -24.23M -25.7M -20.67M -23.12M -16.72M -22.58M -12.17M -10.44M -11.77M -7.35M -7.35M
Interest Income
2.8M 2.79M 3.28M 3.34M 2.22M 2.39M 3.07M 3.67M 3.82M 3.26M 1.93M 2.32M 1.02M n/a n/a n/a n/a n/a
Pretax Income
-49.89M -43.32M -35.54M -34.98M -31.4M -64.39M -20.63M -20.56M -21.87M -17.42M -21.19M -14.4M -21.57M -12.17M -10.44M -11.77M -7.35M -7.35M
Net Income
-49.89M -43.32M -35.54M -34.98M -31.4M -64.39M -20.63M -20.56M -21.87M -17.42M -21.19M -14.4M -21.57M -12.17M -10.44M -11.77M -7.35M -7.35M
Selling & General & Admin
10.35M 8.49M 6.65M 6.15M 5.9M 5.48M 3.54M 4.14M 3.92M 3.7M 3.11M 2.44M 2.23M 1.94M 1.8M 1.68M 1.5M 1.5M
Research & Development
42.34M 37.62M 32.18M 32.17M 27.72M 61.29M 20.16M 20.09M 21.78M 16.98M 20.01M 14.28M 20.36M 10.24M 8.65M 10.09M 5.85M 5.85M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
52.69M 46.11M 38.82M 38.32M 33.62M 66.77M 23.71M 24.23M 25.7M 20.67M 23.12M 16.72M 22.58M 12.17M 10.44M 11.77M 7.35M 7.35M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
52.69M 46.11M 38.82M 38.32M 33.62M 66.77M 23.71M 24.23M 25.7M 20.67M 23.12M 16.72M 22.58M 12.17M 10.44M 11.77M 7.35M 7.35M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Shares Outstanding (Basic)
47.61M 45.07M 38.46M 41.91M 35.01M 33.9M 33.58M 33.58M 33.51M 33.49M 33.49M 33.49M 33.49M 33.49M 33.49M 33.49M 1.28M 1.28M
Shares Outstanding (Diluted)
47.61M 45.07M 38.46M 41.91M 35.01M 33.9M 33.58M 33.58M 33.51M 33.49M 33.49M 33.49M 33.49M 33.49M 33.49M 33.49M 1.28M 1.28M
EPS (Basic)
-1.05 -0.96 -0.84 -0.83 -0.90 -1.90 -0.61 -0.61 -0.65 -0.52 -0.63 -0.43 -0.64 -0.36 -0.31 -0.35 -5.76 -5.76
EPS (Diluted)
-1.05 -0.96 -0.84 -0.83 -0.90 -1.90 -0.61 -0.61 -0.65 -0.52 -0.63 -0.43 -0.64 -0.36 -0.31 -0.35 -5.76 -5.76
EBITDA
-49.89M -43.32M -35.54M -34.98M -31.4M -64.39M -20.63M -20.56M -21.87M -17.42M -21.19M -14.4M -21.57M n/a n/a n/a n/a n/a
EBIT
-49.89M -43.32M -35.54M -34.98M -31.4M -64.39M -20.63M -20.56M -21.87M -17.42M -21.19M -14.4M -21.57M -12.17M -10.44M -11.77M -7.35M -7.35M
Depreciation & Amortization
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 12.17M 10.44M 11.77M 7.35M 7.35M

© 2026 bestshares.com. All rights reserved.